U.S. health officials on Friday approved a nasal spray to treat severe allergic reactions, the first needle-free alternative to shots like EpiPen. The Food and Drug Administration said it approved the ...

Credit: Aptar Pharma. Enbumyst is supplied in a unit-dose nasal spray containing bumetanide 0.5mg per 0.1mL. Enbumyst is not intended for chronic use and should be replaced with oral diuretics as soon ...

The U.S. Food and Drug Administration has approved Pfizer's newest drug on the migraine market, Zavzpret (zavegepant) - the first and only migraine treatment of its kind to be offered in nasal spray.

Forty-two years after approving the potent diuretic Bumex (bumetanide) as both an oral and infused treatment for edema, the FDA has endorsed a new version of the drug to be delivered as a nasal spray.

Please provide your email address to receive an email when new articles are posted on . The FDA approved a rapid-acting nasal spray for the treatment of acute symptomatic paroxysmal supraventricular ...

(RTTNews) - Milestone Pharmaceuticals Inc. (MIST) has received FDA approval for its first commercial product, CARDAMYST nasal spray, for the conversion of acute symptomatic episodes of paroxysmal ...

What Is Enbumyst, and Why Does It Matter? Enbumyst is a new nasal spray form of bumetanide (first approved by the FDA in 1983). It is a type of medicine called a loop diuretic (also known as a “water ...

Ra’anana, Israel, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today ...

The US Food and Drug Administration (FDA) has approved the first intranasal diuretic for heart, liver and kidney disease patients, aiming to prevent a common and costly issue that results in more than ...

What Is Cardamyst, and Why Does It Matter? Cardamyst (etripamil) is a new nasal spray for treating sudden episodes of fast heartbeats, known as paroxysmal supraventricular tachycardia (PSVT), and ...